首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1461503

抗生素抗药性全球市场规模、份额、成长分析（按药物类别、病原体、疾病）- 产业预测，2024-2031 年

Global Antibiotic Resistance Market Size, Share, Growth Analysis, By Drug-class, By Pathogen, By Disease - Industry Forecast 2024-2031

出版日期: 2024年04月02日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球抗生素抗药性市场规模为89.8亿美元，从2023年的101.6亿美元成长到2031年的273.9亿美元，预测期间（2024-2031年）预计复合年增长率为13.19%。

在抗生素抗药性细菌带来的日益严峻的挑战的推动下，全球抗生素抗药性市场正在经历显着扩张。该报告对抗生素抗药性市场的价值链进行了详细分析，并为製造商提供了竞争考察，以在预测期内加强竞争。抗生素抗药性的普遍存在正在危及感染疾病传统治疗方法的有效性，其主要原因是抗生素的滥用和过度使用。医疗机构感染预防措施不足正在加剧抗药性菌株的传播，而正在开发的新抗生素的严重短缺更是雪上加霜。认识到这场危机的紧迫性，各国政府、医疗机构和製药公司越来越多地联合起来，透过各种手段对抗抗生素抗药性。鼓励官民合作关係旨在刺激抗生素创新，抗生素管理计画的采用在优化抗生素使用和遏制抗药性方面正在获得动力。同时，针对医疗保健专业人员和公众的教育宣传活动正在努力改善处方实践并提高对抗生素抗药性的认识。利用基因组学和蛋白质组学等技术进步有望阐明抗药性机制和设计新的治疗方法。噬菌体疗法和免疫疗法等新选择描述了对抗抗生素抗药性的潜在解决方案。抗生素抗药性情况既带来了挑战，也带来了机会，齐心协力对于减轻不断升级的威胁并保障未来有效的细菌感染疾病治疗至关重要。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

辉瑞公司（美国）
默克公司（美国）
强生公司（美国）
诺华公司（瑞士）
葛兰素史克公司（英国）
Achaogen 公司（美国）
Tetraphase Pharmaceuticals, Inc.（美国）
Paratek 製药公司（美国）
Melinta Therapeutics, Inc.（美国）
西普拉有限公司（印度）
罗氏控股公司（瑞士）
赛诺菲（法国）
礼来公司（美国）
拜耳公司（德国）
Cubist Pharmaceuticals, Inc.（美国）
艾尔建公司（爱尔兰）
阿斯特捷利康公司（英国）
梯瓦製药工业股份有限公司（以色列）
迈兰 NV（美国）
Basilea Pharmaceutica Ltd.（瑞士）

简介目录

Product Code: SQMIG35H2182

Global Antibiotic Resistance Market size was valued at USD 8.98 billion in 2022 and is poised to grow from USD 10.16 billion in 2023 to USD 27.39 billion by 2031, growing at a CAGR of 13.19% during the forecast period (2024-2031).

The global market for antibiotic resistance is witnessing significant expansion worldwide, driven by the escalating challenge posed by antibiotic-resistant bacteria. Our comprehensive report offers an in-depth analysis of the Antibiotic Resistance market's value chain, equipping manufacturers with insights to enhance their competitive positioning over the forecasted period. The pervasive issue of antibiotic resistance jeopardizes the efficacy of conventional treatments for infectious diseases, primarily attributed to the rampant misuse and overuse of antibiotics. Inadequate infection prevention measures within healthcare settings further exacerbate the spread of resistant strains, compounded by the alarming shortage of new antibiotics in development. Recognizing the urgency of this crisis, governments, healthcare entities, and pharmaceutical firms are increasingly rallying to combat antibiotic resistance through various means. Encouragement of public-private partnerships aims to stimulate antibiotic innovation, while the adoption of antibiotic stewardship programs gains momentum in optimizing antibiotic usage and curbing resistance. Concurrently, educational campaigns target healthcare practitioners and the general populace to improve prescribing practices and foster awareness about antibiotic resistance. Leveraging technological advancements such as genomics and proteomics holds promise in elucidating resistance mechanisms and devising novel therapeutic approaches. Emerging alternatives like phage therapy and immunotherapy offer potential solutions to counter antibiotic resistance. As the antibiotic resistance landscape presents both challenges and opportunities, concerted efforts are imperative to mitigate its escalating threat and safeguard effective bacterial infection treatment in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibiotic Resistance Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibiotic Resistance Market Segmental Analysis

The global antibiotic resistance market can be segmented based on drug-class, pathogen, disease type, and region. Based on drug class, the market can be divided into beta-lactams, macrolides, tetracyclines, fluoroquinolones, and others. Based on pathogens, the market can be categorized into gram-negative bacteria, gram-positive bacteria, and others. Based on disease types, the market can be categorized into respiratory infections, urinary tract infections, bloodstream infections, and others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Antibiotic Resistance Market

The escalating prevalence of infections caused by antibiotic-resistant bacteria underscores the urgency for the advancement of viable treatment modalities. With conventional antibiotics waning in efficacy, there arises a pressing need for novel antibiotics and alternative interventions to counteract resistant strains. This imperative propels intensive research and developmental endeavors, resulting in the identification of fresh pharmaceuticals and therapeutic strategies to tackle antibiotic resistance. Furthermore, heightened societal consciousness regarding the grave repercussions of antibiotic resistance has galvanized governmental bodies, healthcare institutions, and pharmaceutical enterprises to dedicate resources and undertake initiatives aimed at mitigating this challenge.

Restraints in the Global Antibiotic Resistance Market

The pipeline for developing novel antibiotics is notably constrained despite the escalating menace of antibiotic resistance. Crafting new antibiotics entails navigating a labyrinth of complexities and challenges, demanding substantial investments, time, and specialized knowledge. Yet, obstacles like exorbitant research and development expenses, regulatory hurdles, and minimal returns on investment have dampened antibiotic innovation. This scarcity of fresh antibiotic options severely impairs our capacity to combat antibiotic-resistant infections, emphasizing the pressing imperative for heightened initiatives and incentives to invigorate antibiotic development.

Market Trends of the Global Antibiotic Resistance Market

The increasing threat of antibiotic resistance has prompted a recognition that conventional antibiotic treatments alone may not effectively tackle the issue. Consequently, there's a movement towards investigating alternative strategies to combat bacterial infections. One prominent approach is the progress in phage therapy, where bacteriophages, viruses that infect and destroy bacteria, are utilized to target and eradicate antibiotic-resistant strains. This innovative method presents a promising avenue for addressing antibiotic resistance by precisely targeting harmful bacteria while preserving the beneficial microbiota.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Antibiotic Resistance Market by Drug-class

Market Overview
Beta-lactams
macrolides
tetracyclines
fluoroquinolones
others

Global Antibiotic Resistance Market by Pathogen

Market Overview
Gram-negative bacteria
gram-positive bacteria

Global Antibiotic Resistance Market by Disease

Market Overview
Respiratory infections
urinary tract infections
bloodstream infections
and others

Global Antibiotic Resistance Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Achaogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tetraphase Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Paratek Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Melinta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cubist Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Basilea Pharmaceutica Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments